Cargando…

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE

OBJECTIVES: To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound. METHODS: The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Agostino, Maria Antonietta, Schett, Georg, López-Rdz, Alejandra, Šenolt, Ladislav, Fazekas, Katalin, Burgos-Vargas, Ruben, Maldonado-Cocco, Jose, Naredo, Esperanza, Carron, Philippe, Duggan, Anne-Marie, Goyanka, Punit, Boers, Maarten, Gaillez, Corine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071547/ https://www.ncbi.nlm.nih.gov/pubmed/34528079 http://dx.doi.org/10.1093/rheumatology/keab628

Ejemplares similares

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
por: Felten, Renaud, et al.
Publicado: (2023)

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
por: Kampylafka, Eleni, et al.
Publicado: (2018)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study
por: D'Agostino, Maria-Antonietta, et al.
Publicado: (2016)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Psoriatic Synovitis: Singularity and Potential Clinical Implications
por: Celis, Raquel, et al.
Publicado: (2019)

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
por: D'Agostino, Maria-Antonietta, et al.
Publicado: (2016)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
por: CHELLI, Clara, et al.
Publicado: (2020)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
por: McInnes, Iain B., et al.
Publicado: (2018)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
por: Damiani, Giovanni, et al.
Publicado: (2019)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient
por: Kang, Hyun Jin, et al.
Publicado: (2021)

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?
por: Obeidat, Adham E, et al.
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Synovitis in Psoriatic Arthritis: Immunohistochemistry, Comparisons With Rheumatoid Arthritis, and Effects of Therapy
por: van Kuijk, Arno W. R., et al.
Publicado: (2011)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
por: Mease, Philip, et al.
Publicado: (2022)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis
por: Kampylafka, Eleni, et al.
Publicado: (2020)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
por: Coates, L. C., et al.
Publicado: (2018)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
por: Zhang, Kai-Lin, et al.
Publicado: (2021)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3qqn70rc8q6678bpk5a3gnomu